What is the recommended dose of aztreonam (Aztreonam) for a 60 kg patient with normal renal function (Renal Function Tests) and normal liver function (Liver Function Tests)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Aztreonam Dosing for a 60 kg Patient with Normal Renal and Hepatic Function

For a 60 kg adult patient with normal renal and hepatic function, administer aztreonam 1-2 grams intravenously every 6-8 hours, with the specific dose and interval determined by infection severity. 1

Standard Dosing Regimens by Infection Severity

The dosing of aztreonam follows a tiered approach based on infection type and severity 1:

  • Urinary tract infections: 500 mg or 1 g every 8-12 hours 1
  • Moderately severe systemic infections: 1 g or 2 g every 8-12 hours 1
  • Severe systemic or life-threatening infections: 2 g every 6-8 hours 1

For Pseudomonas aeruginosa infections specifically, 2 g every 6-8 hours is recommended at least initially, regardless of other severity considerations. 1 This higher dosing reflects the organism's relative resistance compared to other Enterobacteriaceae 2, 3.

Route of Administration Considerations

The intravenous route is strongly preferred for 1:

  • Single doses greater than 1 g
  • Bacterial septicemia
  • Localized parenchymal abscesses (e.g., intra-abdominal abscess)
  • Peritonitis
  • Other severe systemic or life-threatening infections

Intramuscular administration may be acceptable for lower-severity infections requiring ≤1 g doses 1.

Pharmacokinetic Rationale

After a 2 g intravenous dose, aztreonam maintains concentrations above the MIC90 for most Enterobacteriaceae for 8 hours and for P. aeruginosa for almost 6 hours 2. The elimination half-life is approximately 1.7 hours in patients with normal renal function 2, 3. Peak serum levels occur within 5 minutes after intravenous administration 2.

Between 60-70% of aztreonam is excreted unchanged in the urine, resulting in urinary concentrations approximating 3,000 mcg/mL two hours after a 1 g intravenous dose 2.

Maximum Daily Dose

The maximum recommended dose is 8 grams per day. 1 This ceiling should not be exceeded even in severe infections.

Duration of Therapy

Continue aztreonam for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained 1. Persistent infections may require treatment for several weeks 1. For complicated intra-abdominal infections specifically, antimicrobial therapy should be limited to 4-7 days unless adequate source control is difficult to achieve 1.

Important Clinical Caveats

No dose adjustment is required for this 60 kg patient with normal renal and hepatic function. 1, 4 Dosage modifications are only necessary when creatinine clearance falls below 30 mL/min/1.73 m² 1, 4.

Aztreonam has no activity against gram-positive bacteria or anaerobes 2, 3, 5. If the infection etiology is unknown or mixed bacterial infection is suspected, aztreonam must be combined with agents active against gram-positive organisms and/or anaerobes. 1, 3, 5, 6 Common combinations include aztreonam with metronidazole for intra-abdominal infections 1.

The drug is not nephrotoxic and represents a safer alternative to aminoglycosides in patients at risk for renal toxicity 2, 3, 7. Aztreonam demonstrates synergistic activity when combined with aminoglycosides against P. aeruginosa and gentamicin-resistant gram-negative rods 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

How and why aztreonam works.

Surgery, gynecology & obstetrics, 1990

Research

The monobactams.

Mayo Clinic proceedings, 1991

Research

Aztreonam: the first monobactam.

The Medical clinics of North America, 1988

Research

Aztreonam in the treatment of serious gram-negative infections in the elderly.

International journal of clinical pharmacology, therapy, and toxicology, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.